Zorevunersen Demonstrates Potential as a Disease-modifying Therapy in Patients with Dravet Syndrome Through Durable Seizure Reduction and Improvements in Cognition, Behavior, and Quality of Life Through 36 Months of Treatment in Open-label Extension Studi

Multiomic Dissection of Large Exome-sequenced Chiari I Malformation Cohort Reveals Convergent PI3K–AKT–mTOR and Chromatin Remodeling Pathways